HYCALIEVA 2.5MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | HYCALIEVA 2.5MG |
|---|---|
| Composition | Topotecan Injection IP 2.5mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
Topotecan Injection IP 2.5mg (Topotecan Injection IP 2.5mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
HYCALIEVA 2.5 mg contains Topotecan, a topoisomerase-I inhibitor belonging to the camptothecin class. It works by stabilizing the topoisomerase-I–DNA complex, causing DNA strand breaks and preventing DNA replication, leading to cancer cell death.
Topotecan is indicated for:
1. Ovarian Cancer
– Metastatic or recurrent disease after platinum-based therapy
2. Small Cell Lung Cancer (SCLC)
– Relapsed or refractory disease
3. Cervical Cancer
– In combination with cisplatin
Common side effects:
• Severe myelosuppression (neutropenia, thrombocytopenia, anemia)
• Nausea, vomiting
• Diarrhea
• Fatigue
Other side effects:
• Alopecia
• Fever
Serious side effects:
• Severe infections due to neutropenia
• Interstitial lung disease (rare)
Regular monitoring of CBC is mandatory before each cycle.
Dosage depends on indication and patient factors.
Common regimens:
• 1.5 mg/m²/day IV for 5 consecutive days
• Cycle repeated every 21 days
2.5 mg vial allows accurate dose calculation.
NOTE: This medicine should be taken only under a doctor’s supervision.